{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:27:02Z","timestamp":1790800022489,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010324","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000}}],"reference-count":94,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010324.pub2","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T22:16:46Z","timestamp":1427494606000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Enzyme replacement and substrate reduction therapy for Gaucher disease"],"prefix":"10.1002","volume":"2015","author":[{"given":"Elad","family":"Shemesh","sequence":"first","affiliation":[{"name":"Israel Defense Forces Medical Corps; Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Deroma","sequence":"additional","affiliation":[{"name":"University Hospital \"Santa Maria della Misericordia\"; Regional Coordinator Centre for Rare Diseases; Piazzale Santa Maria della Misericordia 15 Udine Italy 33100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Bembi","sequence":"additional","affiliation":[{"name":"University Hospital \"Santa Maria della Misericordia\"; Regional Coordinator Centre for Rare Diseases; Piazzale Santa Maria della Misericordia 15 Udine Italy 33100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Deegan","sequence":"additional","affiliation":[{"name":"University of Cambridge and Lysosomal Disorders Unit; Department of Medicine; Addenbrooke's Hospital (PO Box 157) Cambridge UK CB2 0QQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Hollak","sequence":"additional","affiliation":[{"name":"Academic Medical Center; Department of Internal Medicine, Division of Endocrinology & Metabolism; Postbus 22660 Amsterdam Netherlands 1100 DD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal J","family":"Weinreb","sequence":"additional","affiliation":[{"name":"Northwest Oncology Hematology Associates PA; University Research Foundation for Lysosomal Storage Diseases; 8170 Royal Palm Boulevard Coral Springs Florida USA 33433"},{"name":"University of Miami Miller School of Medicine; Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M","family":"Cox","sequence":"additional","affiliation":[{"name":"Addenbrooke's Hospital (Box 157); Department of Medicine; Level 5, Hills Road Cambridge Cambridgeshire UK CB2 0QQ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD010324.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Ben Turkia","year":"2013","journal-title":"American Journal of Hematology"},{"issue":"21","key":"10.1002\/14651858.CD010324.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"Poster: 3214","DOI":"10.1182\/blood.V118.21.3214.3214","article-title":"Two-year safety and tolerability of velaglucerase alfa in patients with type 1 gaucher disease, including patients switched from imiglucerase: phase III trial HGT-GCB-039 and extension [abstract]","volume":"118","author":"Ben Turkia","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0003|cit3","first-page":"S224, Abstract","article-title":"Achievement of therapeutic goals in patients with type 1 gaucher disease (GD1) on velaglucerase alfa or imiglucerase: phase III trials HGT-GCB-039 and extension [abstract]","volume":"34 Suppl 3","author":"Ben Turkia","year":"2011","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0004|cit4","first-page":"S150, Abstract","article-title":"Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U\/KG every other week: 2-year results [abstract]","volume":"35 Suppl 1","author":"Elstein","year":"2012","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0005|cit5","first-page":"S302, Abstract","article-title":"Efficacy of long-term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]","volume":"36 Suppl 2","author":"Zimran","year":"2013","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"10.1002\/14651858.CD010324.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3324\/haematol.10635","article-title":"Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial","volume":"92","author":"Fost","year":"2007","journal-title":"Haematologica"},{"issue":"7","key":"10.1002\/14651858.CD010324.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","article-title":"Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement","volume":"110","author":"Elstein","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0008|cit8","unstructured":"Elstein D Heitner R Dweck A Attias D Atarescu G Zimran A OGT 918 as substrate reduction therapy in type I gaucher disease [abstract] 6th Meeting of the European Haematology Association; 2001 June 21-24; Frankfurt, Germany. 2001 Abstract no: 212"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0009|cit9","first-page":"S150, Abstract","article-title":"Bone mineral density in adults with type 1 gaucher disease receiving velaglucerase alfa 60 U\/KG every other week: 2-year results [abstract]","volume":"35 Suppl 1","author":"Elstein","year":"2012","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0010|cit10","first-page":"S139, Abstract","article-title":"Clinically significant hemoglobin response observed within 3 months following treatment with velaglucerase alfa in patients with type 1 gaucher disease [abstract]","volume":"33 Suppl 1","author":"Gonzalez","year":"2010","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"3","key":"10.1002\/14651858.CD010324.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0012|cit12","first-page":"S302, Abstract","article-title":"Efficacy of long-term velaglucerase alfa on haematological and visceral parameters in patients with type 1 gaucher disease [abstract]","volume":"36 Suppl 2","author":"Zimran","year":"2013","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1","key":"10.1002\/14651858.CD010324.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Grabowski GA Barton NW Pastores G Dambrosia JM Banerjee TK McKee MA Enzyme therapy in gaucher disease type 1: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources [abstract] Blood 1994 226a","DOI":"10.7326\/0003-4819-122-1-199501010-00005"},{"issue":"4","key":"10.1002\/14651858.CD010324.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2008.12.015","article-title":"A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1","volume":"96","author":"Kishnani","year":"2009","journal-title":"Molecular Genetics and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD010324.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher's disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Annals of Neurology"},{"issue":"22","key":"10.1002\/14651858.CD010324.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD010324.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"Abstract no: 21","DOI":"10.1182\/blood.V120.21.2140.2140","article-title":"A multicenter, double-blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]","volume":"120","author":"Zimran","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0019|cit19","first-page":"S301, Abstract","article-title":"A multi-center, double-blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with gaucher disease [abstract]","volume":"36 Suppl 2","author":"Zimran","year":"2013","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0020|cit20","first-page":"S11, Abstract n","article-title":"Long-term safety and efficacy data of taliglucerase alfa, a plant cell expressed recombinant glucocerebrosidase, in the treatment of naive gaucher disease patients [abstract]","volume":"35 Suppl 1","author":"Zimran","year":"2012","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"3","key":"10.1002\/14651858.CD010324.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bcmd.2012.11.001","article-title":"Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease","volume":"50","author":"Dussen","year":"2013","journal-title":"Blood cells, Molecules & Diseases"},{"issue":"7","key":"10.1002\/14651858.CD010324.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/qjmed\/91.7.483","article-title":"Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease","volume":"91","author":"Elstein","year":"1998","journal-title":"QJM: Monthly Journal of the Association of Physicians"},{"issue":"5","key":"10.1002\/14651858.CD010324.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","article-title":"Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy","volume":"104","author":"Wenstrup","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD010324.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.23383","article-title":"Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","volume":"88","author":"Zimran","year":"2013","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0025|cit25","first-page":"S268, Abstract","article-title":"Engage: a phase 3, randomized, double blind, placebo controlled, multi center study to investigate the efficacy and safety of eliglustat in adults with gaucher disease type 1: 9 month results [abstract]","volume":"36 Suppl 2","author":"Ben Turkia","year":"2013","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0026|cit26","first-page":"S268, Abstract","article-title":"Effects of oral eliglustat on bone disease in gaucher disease type 1: results from the randomized, placebo-controlled engage trial [abstract]","volume":"36 Suppl 2","author":"Dasouka","year":"2013","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"7","key":"10.1002\/14651858.CD010324.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1: The ENGAGE Randomized Clinical Trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0028|cit28","first-page":"S268, Abstract","article-title":"Encore: a multi-national, randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 (GD1) patients on enzyme replacement therapy (ERT) who have reached therapeutic goals [abstract]","volume":"36 Suppl 2","author":"Cox","year":"2013","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2-3","key":"10.1002\/14651858.CD010324.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10545-006-0272-5","article-title":"Substrate reduction therapy of glycosphingolipid storage disorders","volume":"29","author":"Aerts","year":"2006","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"6","key":"10.1002\/14651858.CD010324.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10545-012-9523-9","article-title":"Miglustat-induced intestinal carbohydrate malabsorption is due to the inhibition of alpha-glucosidases, but not beta-galactosidases","volume":"35","author":"Amiri","year":"2012","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"6","key":"10.1002\/14651858.CD010324.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"issue":"21","key":"10.1002\/14651858.CD010324.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010324.pub2-BIB0033|cit33","first-page":"85","article-title":"Gaucher disease: gene frequencies in the Ashkenazi Jewish population","volume":"52","author":"Beutler","year":"1993","journal-title":"American Journal of Human Genetics"},{"issue":"451","key":"10.1002\/14651858.CD010324.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1651-2227.2006.tb02398.x","article-title":"Gaucher disease: multiple lessons from a single gene disorder","volume":"95","author":"Beutler","year":"2006","journal-title":"Acta Paediatrica (Oslo, Norway : 1992). Supplement"},{"issue":"10","key":"10.1002\/14651858.CD010324.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/brain\/awq198","article-title":"Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study","volume":"133","author":"Biegstraaten","year":"2010","journal-title":"Brain: a Journal of Neurology"},{"issue":"7040","key":"10.1002\/14651858.CD010324.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/bmj.312.7040.1215","article-title":"Why we need observational studies to evaluate the effectiveness of health care","volume":"312","author":"Black","year":"1996","journal-title":"BMJ (Clinical research ed.)"},{"issue":"7","key":"10.1002\/14651858.CD010324.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1172\/JCI105417","article-title":"Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease.","volume":"45","author":"Brady","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1002\/14651858.CD010324.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","article-title":"The risk of Parkinson's disease in type 1 Gaucher disease","volume":"33","author":"Bultron","year":"2010","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"18","key":"10.1002\/14651858.CD010324.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD010324.pub2-BIB0040|cit40","first-page":"1076","article-title":"Neurological manifestations of type 1 Gaucher's disease: Is a revision of disease classification needed?","volume":"162","author":"Cherin","year":"2006","journal-title":"Revue Neurologique"},{"issue":"3","key":"10.1002\/14651858.CD010324.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bcmd.2012.11.011","article-title":"Phenotype in patients with Gaucher disease and Parkinson disease","volume":"50","author":"Chetrit","year":"2013","journal-title":"Blood Cells, Molecules & Diseases"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1172-6-61","article-title":"Reducing selection bias in case-control studies from rare disease registries","volume":"6","author":"Cole","year":"2011","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"2","key":"10.1002\/14651858.CD010324.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF00293959","article-title":"Late-infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings","volume":"82","author":"Conradi","year":"1991","journal-title":"Acta Neuropathologica"},{"issue":"9214","key":"10.1002\/14651858.CD010324.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD010324.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"10","key":"10.1002\/14651858.CD010324.pub2-BIB0046|cit46","first-page":"1169","article-title":"Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases","volume":"11","author":"Cox","year":"2010","journal-title":"Current Opinion in Investigational Drugs"},{"issue":"5","key":"10.1002\/14651858.CD010324.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1008814105603","article-title":"The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study","volume":"7","author":"Damiano","year":"1998","journal-title":"Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation"},{"issue":"3","key":"10.1002\/14651858.CD010324.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis","volume":"108","author":"Fost","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0049|cit49","unstructured":"Deeks J Higgins J Altman D Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/8904_2012_158","article-title":"Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 italian Gaucher type I patients","volume":"7","author":"Deroma","year":"2013","journal-title":"JIMD reports"},{"issue":"9","key":"10.1002\/14651858.CD010324.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMra0907180","article-title":"New therapeutic approaches to mendelian disorders","volume":"363","author":"Dietz","year":"2010","journal-title":"The New England journal of medicine"},{"issue":"1","key":"10.1002\/14651858.CD010324.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0053|cit53","unstructured":"Genzyme\/Sanofi Prescribed ERT infusions [personal communication] Email to: Neal Weinreb 2013"},{"issue":"4","key":"10.1002\/14651858.CD010324.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010324.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2010.09.005","article-title":"Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage","volume":"46","author":"Giraldo","year":"2011","journal-title":"Blood Cells, Molecules & Diseases"},{"issue":"12","key":"10.1002\/14651858.CD010324.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Goker-Alpan","year":"2004","journal-title":"Journal of Medical Genetics"},{"issue":"1","key":"10.1002\/14651858.CD010324.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bcmd.2010.05.002","article-title":"Enzyme replacement therapy \"drug holiday\": results from an unexpected shortage of an orphan drug supply in Australia","volume":"46","author":"Goldblatt","year":"2011","journal-title":"Blood cells, Molecules & Diseases"},{"issue":"1","key":"10.1002\/14651858.CD010324.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/gte.1997.1.5","article-title":"Gaucher disease: gene frequencies and genotype\/phenotype correlations","volume":"1","author":"Grabowski","year":"1997","journal-title":"Genetic testing"},{"issue":"9645","key":"10.1002\/14651858.CD010324.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD010324.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1","volume":"11","author":"Grabowski","year":"2009","journal-title":"Genetics in Medicine: Official Journal of the American College of Medical Genetics"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0061|cit61","unstructured":"Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD010324.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","article-title":"Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease","volume":"44","author":"Hollak","year":"2010","journal-title":"Blood Cells, Molecules & Diseases"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-6-16","article-title":"Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders","volume":"6","author":"Hollak","year":"2011","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/CE.S20201","article-title":"An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease","volume":"7","author":"Hollak","year":"2012","journal-title":"Core Evidence"},{"issue":"22","key":"10.1002\/14651858.CD010324.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.12968\/bjon.2007.16.22.27768","article-title":"Home therapy for lysosomal storage disorders","volume":"16","author":"Hughes","year":"2007","journal-title":"British Journal of Nursing"},{"issue":"5","key":"10.1002\/14651858.CD010324.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0022-2275(20)38673-9","article-title":"Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase","volume":"28","author":"Inokuchi","year":"1987","journal-title":"Journal of Lipid Research"},{"issue":"6","key":"10.1002\/14651858.CD010324.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","article-title":"The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis","volume":"160","author":"Kaplan","year":"2006","journal-title":"Archives of Pediatrics & Adolescent Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010324.pub2-BIB0068|cit68","first-page":"158","article-title":"Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and\/or enzyme replacement therapy","volume":"2","author":"Kauli","year":"2000","journal-title":"Israel Medical Association Journal"},{"issue":"8","key":"10.1002\/14651858.CD010324.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/jbmr.1680","article-title":"Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"27","author":"Khan","year":"2012","journal-title":"Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research"},{"issue":"12","key":"10.1002\/14651858.CD010324.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"910","DOI":"10.7326\/0003-4819-158-12-201306180-00009","article-title":"A historic moment for open science: the yale university open data access project and medtronic","volume":"158","author":"Krumholz","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010324.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","article-title":"Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study","volume":"51","author":"Kuter","year":"2013","journal-title":"Blood Cells, Molecules & Diseases"},{"issue":"3","key":"10.1002\/14651858.CD010324.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bcmd.2007.09.002","article-title":"Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy","volume":"40","author":"Langeveld","year":"2008","journal-title":"Blood Cells, Molecules & Diseases"},{"key":"10.1002\/14651858.CD010324.pub2-BIB0073|cit73","first-page":"177","article-title":"The pathology of Gaucher disease","volume":"95","author":"Lee","year":"1982","journal-title":"Progress in Clinical and Biological Research"},{"issue":"20","key":"10.1002\/14651858.CD010324.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD010324.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"McEachern","year":"2007","journal-title":"Molecular Genetics and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD010324.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"9041","key":"10.1002\/14651858.CD010324.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0140-6736(96)04451-0","article-title":"Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease","volume":"348","author":"Mistry","year":"1996","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD010324.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD010324.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells, Molecules & Diseases"},{"issue":"8","key":"10.1002\/14651858.CD010324.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.2337\/dc13-0356","article-title":"Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)","volume":"36","author":"Nathan","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD010324.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cmdc.201000469","article-title":"Second-generation iminoxylitol-based pharmacological chaperones for the treatment of Gaucher disease","volume":"6","author":"Oulaidi","year":"2011","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1002\/14651858.CD010324.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/11318540-000000000-00000","article-title":"Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease","volume":"24","author":"Pastores","year":"2010","journal-title":"BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy"},{"issue":"11","key":"10.1002\/14651858.CD010324.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","article-title":"N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis","volume":"269","author":"Platt","year":"1994","journal-title":"The Journal of Biological Chemistry"},{"issue":"12","key":"10.1002\/14651858.CD010324.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"912","DOI":"10.7326\/0003-4819-158-12-201306180-00010","article-title":"Meta-analysis of Trials of Recombinant Human Bone Morphogenetic Protein-2: What Should Spine Surgeons and Their Patients Do With This Information?","volume":"158","author":"Resnick","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD010324.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","article-title":"Gaucher disease and cancer incidence: a study from the Gaucher Registry","volume":"105","author":"Rosenbloom","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD010324.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells, Molecules & Diseases"},{"issue":"3","key":"10.1002\/14651858.CD010324.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","article-title":"Gaucher disease: a comprehensive review","volume":"18","author":"Rosenbloom","year":"2013","journal-title":"Critical Reviews in Oncogenesis"},{"issue":"1-2","key":"10.1002\/14651858.CD010324.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \"simple\" disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Molecular Genetics and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD010324.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Molecular Genetics and Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD010324.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10545-010-9175-6","article-title":"Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy","volume":"33","author":"Stein","year":"2010","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"5","key":"10.1002\/14651858.CD010324.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005792-198509000-00003","article-title":"Skeletal complications of Gaucher disease","volume":"64","author":"Stowens","year":"1985","journal-title":"Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010324.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010324.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcmd.2010.05.001","article-title":"Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply","volume":"46","author":"Zimran","year":"2011","journal-title":"Blood Cells, Molecules & Diseases"},{"issue":"2","key":"10.1002\/14651858.CD010324.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood cells, molecules & diseases"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD010324.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T13:57:39Z","timestamp":1721138259000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010324.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":94,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010324.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}